Literature DB >> 15248908

[Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma].

Yin-Nong Zhao1, Ji Cao, Fei-Xiang Wu, Chao Ou, Wei-Ping Yuan, Qin-Guo Mo, Wei Wei, Yuan Li, Jian-Jia Su, An-Min Liang.   

Abstract

BACKGROUND &
OBJECTIVE: Many evidences demonstrated that the epidermal growth factor receptor (EGFR) subfamily played an important role in they initiation and progression of various cancers. But it is not clear whether there is a relationship between EGFR and hepatocellular carcinoma (HCC). The aims of the present study were to explore the expression and significance of the epidermal growth factor (EGF) mRNA and EGFR mRNA in human HCC tissues.
METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was employed to determine the expression of EGF mRNA and EGFR mRNA in 60 HCC tissues and their adjacent liver tissues.
RESULTS: The positive rate of EGF mRNA was significantly lower in the HCC tissue (60%, 36/60) than in the adjacent liver tissue (80%, 48/60) (P< 0.05). The positive rate of EGFR mRNA in the HCC tissue (60%, 36/60) was markedly higher than in the adjacent liver tissue (41.67%, 25/60) (P< 0.05). The expression of EGFR mRNA in the HCC tissue was significantly correlated with the clinical stage, the portal vein tumor thrombus, the presence of extrahepatic metastasis, and the recurrence of tumor, the number of tumor, but not correlated with the diameter of tumor, the level of serum alpha-fetoprotein (AFP), the differentiation of tumor and the liver cirrhosis in the adjacent tissue. The detectable rate of EGF mRNA was correlated with the diameter of tumor but not correlated with the clinical stage, the portal vein tumor thrombus, the presence of extrahepatic metastasis, the recurrence of tumor, the number of tumor, the level of serum AFP, the differentiation of tumor and the liver cirrhosis in the adjacent tissue.
CONCLUSIONS: EGF may not be involved in the initiation and progression of HCC, whereas, EGFR relates to the initiation and progression and the recurrence of HCC. EGFR can be considered as a marker for predicting the metastasis and recurrence of HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248908

Source DB:  PubMed          Journal:  Ai Zheng


  9 in total

Review 1.  Crossroads of PI3K and Rac pathways.

Authors:  Carlo C Campa; Elisa Ciraolo; Alessandra Ghigo; Giulia Germena; Emilio Hirsch
Journal:  Small GTPases       Date:  2015-05-05

2.  Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.

Authors:  Kesang Li; Suying Qian; Mengmeng Huang; Mengjie Chen; Ling Peng; Jianwen Liu; Wen Xu; Jianfen Xu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

3.  Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.

Authors:  Hua Jiang; Huamao Wang; Zhonghua Tan; Suwen Hu; Hai Wang; Bizhi Shi; Lin Yang; Peiyong Li; Jianren Gu; Hongyang Wang; Zonghai Li
Journal:  J Biol Chem       Date:  2010-12-16       Impact factor: 5.157

4.  Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays.

Authors:  Evangelos Tsiambas; Loukas Manaios; Costas Papanikolopoulos; Dimitrios N Rigopoulos; Dimitrios Tsounis; Andreas Karameris; Aspasia Soultati; Antigoni Koliopoulou; Christos Kravvaritis; Theodoros Sergentanis; Efstratios Patsouris; Spyridon Dourakis
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

5.  Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.

Authors:  Fatma Shehata; Nihad Abdel Monem; Mohamed Sakr; Samar Kasem; Mahmoud Balbaa
Journal:  Med Oncol       Date:  2013-08-03       Impact factor: 3.064

Review 6.  Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Authors:  Massimiliano Berretta; Carla Cavaliere; Lara Alessandrini; Brigida Stanzione; Gaetano Facchini; Luca Balestreri; Tiziana Perin; Vincenzo Canzonieri
Journal:  Oncotarget       Date:  2017-02-21

7.  Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma.

Authors:  Jie Cai; Xuehua Sun; Han Guo; Xiaoye Qu; Hongting Huang; Chang Yu; Hailong Wu; Yueqiu Gao; Xiaoni Kong; Qiang Xia
Journal:  Oncogenesis       Date:  2020-12-04       Impact factor: 7.485

8.  Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology.

Authors:  Ho-Sung Lee; In-Hee Lee; Sang-In Park; Minho Jung; Seung Gu Yang; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-09       Impact factor: 2.650

Review 9.  Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Florin Graur; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.